

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number  
**WO 02/10161 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 417/12**,  
417/14, C07C 69/618, 67/343, 59/74, 51/373, 69/73,  
67/31, 67/333

08525 (US). **SUNDEEN, Joseph, E.** [US/US]; 1108 Pratt  
Drive, Yardley, PA 19067 (US). **ZHAO, Rulin** [CA/US];  
42 Manley Road, Pennington, NJ 08534 (US).

(21) International Application Number: PCT/US01/14154

(74) Agents: **ALGIERI, Aldo, A.** et al.; Bristol-Myers Squibb  
Co., Lawrenceville-Princeton Road, P.O. Box 4000,  
Princeton, NJ 08543 (US).

(22) International Filing Date: 2 May 2001 (02.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/616,627 26 July 2000 (26.07.2000) US  
09/616,629 26 July 2000 (26.07.2000) US  
09/746,059 22 December 2000 (22.12.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):  
**BRISTOL-MYERS SQUIBB COMPANY** [US/US];  
Lawrenceville-Princeton Road, P.O. Box 4000, Princeton,  
NJ 08543-4000 (US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **CHEN, Bang-Chi**  
[CN/US]; Marion Drive, Plainsboro, NJ 08536 (US). **KIM,**  
**Kyoung, S.** [US/US]; 252 Forest Lane, North Brunswick,  
NJ 08902 (US). **KIMBALL, S., David** [US/US]; 13  
Charred Oak Lane, East Windsor, NJ 08520 (US).  
**MISRA, Raj, N.** [US/US]; 12 Eaton Place, Hopewell, NJ

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES




(57) Abstract: The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazole compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup> and X are as defined in the specification. Compounds of formula (I) are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention also concerns a new process for the preparation of formylarylacetates and formylarylacetic acids.

## PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES

The present invention concerns new processes for the preparation of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazoles and analogs, inhibitors of cyclin dependent kinases.

The 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazole compounds of formula I



or a pharmaceutically acceptable salt thereof, wherein:

10  $R^1, R^2, R^4, R^5, R^6, R^8, R^9, R^{12}$  and  $R^{13}$  are each independently hydrogen, alkyl, aryl or heteroaryl;

$R^3, R^7, R^{10}$  and  $R^{11}$  are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; and

X is CH or N,

15 are novel, potent inhibitors of cyclin dependent kinases (cdks). They are useful in the therapy of proliferative diseases, for example, cancer, inflammation, autoimmune diseases such as arthritis, viral diseases, fungal diseases, chemotherapy-induced alopecia, neurodegenerative disorders such as Alzheimer's disease and cardiovascular disease. More specifically, the compounds of formula I are useful in the treatment of a variety of  
20 cancers such as bladder, breast, colon, kidney, liver and lung cancers.

The preparation of 5-(2-oxazolylalkylthio)-2-aminothiazoles, key intermediates in the synthesis of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazoles of formula I, has been described (K. S. Kim *et al.*, WO 9924416, May 20, 1999 and corresponding U.S. Patent No. 6,040,321).

5           4-Formylphenylacetic acid has been previously prepared from ethyl phenylacetate in four steps which provided <15% overall yield (J. W. Baker *et al.*, *J. Chem. Soc.* **1956**, 404).

          The reaction of 4-bromophenylacetic acid or ester with alkyl acrylates using palladium catalysts to give 4-(2-alkoxycarbonylvinyl)phenylacetic acid or ester has been  
10       previously reported in the literature (J. W. Tilley *et al.*, *J. Med. Chem.* **1991**, 34, 1125; A. Cerri *et al.*, *J. Heterocycl. Chem.* **1993**, 30, 1581). The oxidation of  $\beta$ -arylacrylates to give aryl aldehydes has also been reported (G. Cainelli *et al.*, *Synthesis*, **1989**, 47; D. G. Lee *et al.*, *Can. J. Chem.* **1972**, 50; D. G. Lee *et al.*, *Liebigs Ann. Chem.* **1993**, 503; S. Antus *et al.*, *Liebigs Ann. Chem.* **1993**, 105).

15

          This invention concerns new efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazoles and analogs. The processes involve new strategy for the preparation of formylarylacetic acids, key intermediates in the synthesis of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazoles and analogs, inhibitors of cyclin  
20       dependent kinases.

          The present invention relates to new, more efficient processes for the preparation of formylarylacetic acids with application to the synthesis of 5-(2-oxazolylalkylthio)-2-


arylacetylaminothiazoles and analogs, inhibitors of cyclin dependent kinases. The processes involve reaction of haloarylacetic acids or esters II with olefins III to give vinylarylacetic acids or esters IV. Oxidation of IV with an oxidizing reagent gives formylarylacetic acids or esters V. Compared to the previous process which takes four  
5 steps and has yields less than 15%, the process of the invention can obtain the formylacetic acids or esters in only two steps and at substantially higher yields.

Subsequent coupling of formylarylacetic acids or esters V with 5-(2-oxazolylalkylthio)-2-aminothiazoles VI produces amides VII. Reductive amination of the amide VII with amines affords 5-(2-oxazolylalkylthio)-2-  
10 (aminoalkyl)arylacetylaminothiazoles I, inhibitors of cyclin dependent kinases.

Alternatively, compounds of formula I can be prepared by coupling of haloalkylarylacetic acids VIII with 5-(2-oxazolylalkylthio)-2-aminothiazoles VI followed by aminolysis of the resulting amides IX with amines.

The above-described reactions are illustrated in the below Scheme 1.

Scheme 1



In formulas I-IX of Scheme 1, the following terms apply:

R, R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>12</sup> and R<sup>13</sup> are each independently hydrogen, alkyl, aryl or heteroaryl;

R<sup>3</sup>, R<sup>7</sup>, R<sup>10</sup> and R<sup>11</sup> are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy;

W is halogen or sulfonate (RSO<sub>2</sub>O<sup>-</sup>, CF<sub>3</sub>SO<sub>2</sub>O<sup>-</sup>, *etc.*);

X is CH or N;

Y is CHO, C(O)R, COOR, CONRR<sup>1</sup>, CN, NO<sub>2</sub>, SO<sub>2</sub>OR or SO<sub>2</sub>NRR<sup>1</sup>; and

Z is hydrogen, CHO, C(O)R, COOR, CONRR<sup>1</sup>, CN, NO<sub>2</sub>, SO<sub>2</sub>OR or SO<sub>2</sub>NRR<sup>1</sup>.

Listed below are definitions of various terms used to describe the compounds involved in the processes of the present invention. These definitions apply to the terms as they are used throughout the specification (unless specifically indicated otherwise) either individually or as part of a larger group. It should be noted that any heteroatom with unsatisfied valences is assumed to have the hydrogen atom to satisfy the valences.

The term "alkyl" or "alk" (*i.e.*, derivative forms of alkyl) refers to optionally substituted straight chain, branched or cyclic monovalent alkane (saturated hydrocarbon) derived radicals containing from 1 to 12 carbon atoms. When substituted, alkyl groups may be substituted with up to four substituent groups at any available point of attachment. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and the like. The alkyl can be optionally substituted with one or more halogens or alkyl groups such as, for example, trifluoromethyl, 4,4-dimethylpentyl, 2,2,4-trimethylpentyl, *etc.*

The term "aryl" or derivative forms thereof refers to monocyclic or bicyclic aromatic rings, *e.g.*, phenyl, substituted phenyl and the like, as well as groups which are fused, *e.g.*, naphthyl, phenanthrenyl and the like, containing from 6 to 30 carbon atoms. An aryl group can thus contain at least one ring having 6 atoms, with up to five such rings being present, containing up to 22 or 30 atoms therein, depending upon optionally alternating (resonating) double bonds between carbon atoms or suitable heteroatoms. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthryl, biphenyl and the like.

The term "halogen" or "halo" refers to chlorine, bromine, fluorine or iodine, with bromine being the preferred halogen. The term "heteroaryl" refers to a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing at least one heteroatom, O, S or N, in which a carbon or nitrogen atom is the point of attachment, and in which one or two additional carbon atoms is optionally replaced by a heteroatom selected from O or S, and in which from 1 to 3 additional carbon atoms are optionally replaced by nitrogen heteroatoms, said heteroaryl group being optionally substituted as described herein. Exemplary heteroaryl groups include, but are not limited to, thienyl, furyl, pyrrolyl, pyridinyl, imidazolyl, pyrrolidinyl, piperidinyl, thiazolyl, oxazolyl, triazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyridazinyl, pyrimidinal, triazinylazepinyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl, benzofurazanyl, *etc.* The heteroaryl groups can be optionally substituted by one or more groups which include, but are not limited to, halogen, alkyl, alkoxy, hydroxy, carboxy,

carbamoyl, alkyloxycarbonyl, trifluoromethyl, cycloalkyl, nitro, cyano, amino, alkylS(O)<sub>m</sub> (where m = 0, 1 or 2), thiol and the like.

The term "pharmaceutically acceptable salt" refers to those salts of the biologically active compounds which do not significantly or adversely affect the pharmaceutical properties of the compounds, such as, for example, toxicity, efficacy, *etc.* and include those salts which are conventionally employed in the pharmaceutical industry. Suitable examples of salts include, but are not limited to, those formed with inorganic or organic acids such as hydrochloride, hydrobromide, sulfate, phosphate, *etc.* Also included, particularly for the intermediate compounds of the invention, are salts which are unsuitable for pharmaceutical utility but which can be employed otherwise, for example, for isolation or purification of free active compounds or their pharmaceutically acceptable salts.

All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The definition of the compounds employed in the processes of the invention embraces all possible stereoisomers and their mixtures. The definition further embraces the racemic forms and the isolated optical isomers having the specified activity. The racemic forms can be resolved by physical methods such as, for example, fractional crystallization, separation or crystallization of diastereomeric derivatives or separation by chiral column chromatography. The individual optical isomers can be obtained from the racemates by conventional methods such as, for example, salt formation with an optically active acid followed by crystallization.



It should be understood that solvates (*e.g.*, hydrates) of the compounds of formula I and the intermediate compounds are also within the scope of the present invention. Methods of solvation are generally known in the art. Therefore, the compounds useful in the processes of this invention may be in the free or hydrate form.

5           As set forth in Scheme 1, the process for the preparation of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazoles and analogs involves the following transformations:

          (a) reacting a haloarylacetate II with an olefin III in the presence of a palladium catalyst in a suitable solvent or solvent mixtures to give a vinyl-substituted arylacetate IV  
10   such as vinylarylacetate.

          It should be appreciated that the term "haloarylacetate" for purposes of the present invention includes both haloarylacetic acids and esters. Additionally, a sulfonate, for example,  $\text{RSO}_2\text{O}^-$  (where R is alkyl, aryl or heteroaryl),  $\text{CF}_3\text{SO}_2\text{O}^-$  and the like, may be substituted for the halogen in the arylacetate or arylacetic acid starting compounds.

15   The preferred haloarylacetates are haloarylacetic acids with bromophenylacetic acids, such as, for example, 4-bromophenylacetic acid, most preferred. The olefin includes alkenes and polymers derived from an alkene such as ethyl or methyl acrylate. The palladium catalysts include, but are not limited to, palladium acetate or diacetate, palladium halides, *etc.*, with the palladium diacetate preferred. Other standard catalysts  
20   may be employed although less conveniently. A conventional ligand for the palladium catalyst such as trialkyl or triarylphosphine can also be employed. Suitable solvent(s) include solvents such as hydrocarbons, ethers, amides, for example, dimethylformamide ("DMF"), ketones, *etc.*, or mixtures thereof, with amides such as DMF preferred.

(b) reacting the vinyl-substituted arylacetate IV, like vinylarylacetate, obtained in step (a) with an oxidizing reagent in a suitable solvent or solvent mixtures to give a formylarylacetate V.

The oxidizing reagent includes, but is not limited to, O<sub>3</sub>, KMnO<sub>4</sub>, NaIO<sub>4</sub>/OsO<sub>4</sub>,  
5 *etc.*, with NaIO<sub>4</sub>/OsO<sub>4</sub> preferred. Suitable solvent(s) include solvents such as hydrocarbons, ethers, esters, amides, and the like, mixtures thereof, or aqueous mixtures thereof, with an ether and water mixture preferred.

For example, the oxidative cleavage of the double bond of formula IV by a reagent such as osmium tetroxide with sodium periodate in a dioxane/water mixture gives  
10 the desired vinyl-substituted arylacetic acid or arylacetate, such as formylphenylacetic acid or formylphenylacetate.

(c) reacting the formylarylacetate V obtained in step (b) with a 5-(2-oxazolylalkylthio)-2-aminothiazole compound VI in the presence of a coupling reagent and in a suitable solvent or solvent mixtures to give an amide VII.

15 The 5-(2-oxazolylalkylthio)-2-aminothiazoles include 5-(5-substituted-2-oxazolyl-alkylthio)-2-aminothiazole compounds with 5-(5-*t*-butyl-2-oxazolylalkylthio)-2-amino-thiazole preferred. The coupling reagents include, but are not limited to, carbodiimides, haloformates, thionyl halide and the like, with thionyl halide preferred. Suitable solvent(s) include aprotic solvents such as hydrocarbons, halogenated  
20 hydrocarbons, ethers, esters, *etc.*, with halogenated hydrocarbons such as dichloromethane preferred.

(d) reacting the amide VII obtained in step (c) with an amine in the presence of a reducing reagent in a suitable solvent or solvent mixtures to give 5-(2-oxazolylalkylthio)-2-(aminoalkyl)arylacetylaminothiazole I.

The amine used in reaction (d) includes primary and secondary amines with primary aliphatic amines preferred. The reducing reagents include, but are not limited to, NaBH<sub>4</sub>, NaBH(OAc)<sub>3</sub>, Et<sub>3</sub>SiH/TFA and the like with NaBH(OAc)<sub>3</sub> preferred. Suitable solvent(s) include hydrocarbons, halogenated hydrocarbons, ethers, esters, *etc.*, or mixtures thereof, with ethers such as tetrahydrofuran ("THF") preferred.

Alternatively, the compounds of formula I can be prepared by:

(c') reacting the haloalkylarylacetate VIII with a 5-(2-oxazolylalkylthio)-2-aminothiazole compound VI in the presence of a coupling reagent and in a suitable solvent or solvent mixtures to give an amide IX.

The 5-(2-oxazolylalkylthio)-2-aminothiazoles include 5-(5-substituted-2-oxazolyl-alkylthio)-2-aminothiazole compounds with 5-(5-t-butyl-2-oxazolylalkylthio)-2-amino-thiazole preferred. The coupling reagents include, but are not limited to, carbodiimides, haloformates, thionyl halide and the like, with the former preferred, for example, an alkylcarbodiimide. Suitable solvent(s) include aprotic solvents such as hydrocarbons, halogenated hydrocarbons, ethers, esters, *etc.*, with halogenated hydrocarbons such as dichloromethane preferred.

For instance, treatment of haloalkylarylacetate or haloalkylarylacetic acid VIII such as haloalkylphenylacetate or haloalkylphenylacetic acid with 5-(2-oxazolylalkylthio)-2-aminothiazole VI provides a haloalkyl-substituted phenylacetamide IX.

(d') reacting the amide IX obtained in step (c') with an amine in a suitable solvent or solvent mixtures to give 5-(2-oxazolylalkylthio)-2-(aminoalkyl)arylacetylaminothiazole I.

The amine used in reaction (d') includes primary and secondary amines with primary aliphatic amines preferred. Suitable solvent(s) include hydrocarbons, halogenated hydrocarbons, ethers, esters, amides, *etc.*, with amides such as DMF preferred.

For example, the reaction under reductive amination conditions with a primary or secondary amine in the presence of sodium cyanoborohydride or hydrogen in the presence of a catalyst gives the compounds of formula I.

Alternatively, the aldehydes of formula VII may be reacted with an organometallic reagent such as methylmagnesium bromide in a suitable solvent or solvent mixture, such as, for example, ether to give an alcohol derivative. The alcohol derivative is converted to its corresponding halide such as a chloride by a chlorinating agent such as thionyl chloride. The halide compound such as the chloride compound may then be converted to a compound of formula I by reaction with an excess of a primary or secondary amine in a suitable solvent such as ethanol.

The starting compounds of Scheme 1 are commercially available or may be prepared by methods known to one of ordinary skill in the art.

To further illustrate Scheme 1, a process to make formylphenylacetic acids with application to the synthesis of 5-(5-t-butyl-2-oxazolylmethylthio)-2-[(aminomethyl)phenyl-acetyl]aminothiazoles and analogs thereof, for example, starts with the reaction of halophenylacetic acids II such as bromophenylacetic acid


( $R=R^1=R^2=R^3=H$ ,  $X=Br$ ) with alkyl acrylate III such as ethyl acrylate ( $R^4=Z=H$ ,  $Y=CO_2Et$ ) to give (2-ethoxycarbonyl)vinylphenylacetic acids IV ( $R=R^1=R^2=R^3=R^4=Z=H$ ,  $Y=CO_2Et$ ). Oxidation of IV with a suitable oxidizing reagent gives formylphenylacetic acids V ( $R=R^1=R^2=R^3=R^4=H$ ). Coupling of V with 5-(5-t-butyl-2-oxazolylalkylthio)-2-aminothiazole VI ( $R^6=R^7=R^8=R^9=R^{10}=H$ ,  $R^{11}=t-Bu$ ) produces amides VII ( $R^1=R^2=R^3=R^4=R^6=R^7=R^8=R^9=R^{10}=H$ ,  $R^{11}=t-Bu$ ). Reductive amination of VII with amines affords 5-(5-t-butyl-2-oxazolylalkylthio)-2-(aminomethyl)phenylacetyl-amino-thiazoles I, inhibitors of cyclin dependent kinases. Alternatively, compounds of formula I can be prepared by coupling of haloalkylphenylacetic acids VIII such as bromomethylphenylacetic acid ( $R=R^1=R^2=R^3=R^4=R^5=H$ ) with 5-(5-t-butyl-2-oxazolylalkylthio)-2-aminothiazole VI followed by aminolysis of the resulting amides IX with amines.

The following examples demonstrate certain aspects of the present invention. However, it is to be understood that these examples are for illustration only and do not purport to be wholly definitive as to conditions and scope of this invention. It should be appreciated that when typical reaction conditions (*e.g.*, temperature, reaction times, *etc.*) have been given, the conditions both above and below the specified ranges can also be used, though generally less conveniently. The examples are conducted at room temperature (about 23°C to about 28°C) and at atmospheric pressure. All parts and percents referred to herein are on a weight basis and all temperatures are expressed in degrees centigrade unless otherwise specified.

A further understanding of the invention may be obtained from the non-limiting examples which follow below.

## EXAMPLE 1

## A. Preparation of 4-[2-(Ethoxycarbonyl)vinyl]phenylacetic Acid




To a stirred solution of 4-bromophenylacetic acid (43.0 g, 200 mmol) in dimethyl  
5 formamide (400 mL) in a round bottom flask under nitrogen atmosphere at room  
temperature was added ethyl acrylate (43.3 mL, 400 mmol), palladium diacetate (0.90 g,  
4 mmol), triphenylphosphine (2.10 g, 8 mmol), and diisopropylethylamine (87.2 mL, 500  
mmol). The reaction mixture was heated to 100°C for 43 hours, cooled to room  
temperature, and hydrochloric acid (1N, 1 L) was added. To the reaction mixture was  
10 added ethyl acetate (500 mL), the aqueous layer was extracted with ethyl acetate (2 x 500  
mL), and the combined organic layers washed with hydrochloric acid (1N, 500 mL),  
water (500 mL) and saturated sodium chloride solution (250 mL), then dried over sodium  
sulfate, filtered and evaporated *in vacuo* to provide the title compound as a mixture of cis  
and trans isomers (46.9 g, 100%).

15

## EXAMPLE 2

## B. Preparation of 4-Formylphenylacetic Acid




To a stirred solution of the title compound of Example 1 (46.9 g, 200 mmol) in  
20 dioxane (500 mL) and water (500 mL) was added osmium tetroxide (0.5 g, 4% in water),  
followed by sodium periodate (85.56 g, 400 mmol). The reaction mixture was monitored  
by HPLC, stirred for 1 hour and N-methylmorpholine (1.0 g) was added, followed by  
additional osmium tetroxide (1.0 g) after another 16 hours. After 4 hours stirring at room  
temperature, additional sodium periodate (40 g) was added, the reaction stirred for 21  
25 hours, filtered, and the filter cake washed with ethyl acetate (500 mL). The phases were  
separated, the aqueous layer extracted with ethyl acetate (500 mL), the remaining  
aqueous layer acidified with hydrochloric acid (30 mL), extracted with ethyl acetate (500

mL), and the combined organic phases washed with water (500 mL), saturated sodium chloride solution (250 mL), dried over sodium sulfate, filtered and the solvent removed *in vacuo*. The wet solid was triturated with methyl tert-butyl ether (50 mL) and to the resulting slurry was added pentane (100 mL). The slurry was filtered, the solid product was washed with pentane (2 X 25 mL) and dried to give the title compound (12.4 g, 38%). HPLC: 2.19 min (YMC S5 ODS column 4.6 x 50 mm, 10-90% aqueous methanol over 4 minutes containing 0.2% phosphoric acid, 4 mL/min, monitoring at 220 nm). <sup>1</sup>H NMR (d<sub>6</sub>-DMSO): δ 9.99 (s, 1H), 7.85-7.87 (d, 2H), 7.49-7.51 (d, 2H); 3.72 (s, 3H).

## EXAMPLE 3


## C. Preparation of 5-(5-t-Butyl-2-oxazolylalkylthio)-2-(4-formylphenyl)-acetylaminothiazole



Oxalyl chloride (2.0 M in CH<sub>2</sub>Cl<sub>2</sub>, 9.1 mL, 18.2 mmol, 3 eq) was added slowly to a solution of the title compound of Example 2 (2.0 g, 12.2 mmol, 2 eq) in CH<sub>2</sub>Cl<sub>2</sub> at 0°C. The resultant acyl chloride containing reaction mixture was added to a solution of 2-amino-5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]thiazole dropwise (1.64 g, 6.09 mmol) and triethylamine (3.2 mL) in dichloromethane. The reaction was stirred at 0°C for 5 minutes and then allowed to warm to room temperature. After 30 minutes, saturated aqueous NaHCO<sub>3</sub> was added with CH<sub>2</sub>Cl<sub>2</sub> (220 mL), the organic extract washed with saturated aqueous NaHCO<sub>3</sub>, 0.1N HCl, saturated NaCl, and dried over MgSO<sub>4</sub>. Concentration *in vacuo* gave a brown oil which was triturated with hexane followed by ethyl acetate to provide 1.03 g of yellowish solid. An additional 1.02 g of material was obtained from the filtrate by flash chromatography on silica gel eluting with a gradient of 50-60% ethyl acetate in hexane to provide a total of 2.05 g (81%) of the title compound. HPLC: 97% at 3.90 min (YMC S5 ODS column 4.6 x 50 mm, 10-90% aqueous methanol over 4 minutes containing 0.2% phosphoric acid, 4 mL/min, monitoring at 220 nm).

## EXAMPLE 4

## D. Preparation of 5-(5-t-Butyl-2-oxazolylalkylthio)-2-[4-(3-hydroxy-2,2-dimethylpropylaminomethyl)phenyl]acetylaminothiazole




5 To the title compound of Example 3 (1.1 g, 2.65 mmol, 1 eq) dissolved in 20 mL of tetrahydrofuran and cooled to 0°C was added 3-amino-2,2-dimethyl-1-propanol (1.0 g, 9.7 mmol, 3.7 eq), followed by acetic acid (1 mL) and sodium triacetoxyborohydride (2.6 g, 12.3 mmol, 4.6 eq). The reaction was stirred at room temperature for 1 hour. Aqueous NaHCO<sub>3</sub> was added, and the mixture was extracted with ethyl acetate. The organic

10 extracts were washed with water, dried over MgSO<sub>4</sub>, and concentrated *in vacuo*. The material was acidified by addition of 4N HCl in dioxane to a solution in methanol. The product was also purified by flash chromatography on silica gel eluting with 10% methanol in ethyl acetate with 2.7% triethylamine to provide 530 mg (40%) of the title compound as a beige solid. HPLC: 97% at 3.28 min (YMC S5 ODS column 4.6 x 50

15 mm, 10-90% aqueous methanol over 4 minutes containing 0.2% phosphoric acid, 4 mL/min, monitoring at 220 nm).

## EXAMPLE 5

## C' Preparation of 5-(5-t-Butyl-2-oxazolylalkylthio)-2-(4-bromo-methylphenyl)acetylaminothiazole



1,3-Dicyclohexylcarbodiimide (7.18 g, 34.8 mmol, 1.25 eq) was added to a mixture of 5-(5-t-butyl-2-oxazolylalkylthio)-2-aminothiazole (7.5 g, 27.8 mmol, 1 eq) and 4-bromomethylphenylacetic acid (7.97 g, 34.8 mmol, 1.25 eq) in 175 mL of CH<sub>2</sub>Cl<sub>2</sub>




at 0°C. The reaction mixture was allowed to warm to room temperature. After 30 minutes LC/MS indicated that the reaction was complete, the mixture was filtered and concentrated *in vacuo* onto 20 g of silica gel. The material was purified by flash chromatography on silica gel eluting with 60% ethyl acetate in hexane to provide 11.5 g (83%) of the title compound as a yellow solid.

In an alternative method of preparation, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (13.8 g, 72 mmol, 2 eq) was added to a mixture of 5-(5-t-butyl-2-oxazolylalkylthio)-2-aminothiazole (2.0 g, 7.42 mmol, 1 eq) and 4-bromomethyl phenylacetic acid (2.60 g, 11.3 mmol, 1.5 eq) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) under N<sub>2</sub> at room temperature. After 1 hour, the reaction was diluted with 20 mL of ethyl acetate and washed with saturated aqueous NaHCO<sub>3</sub> (2 x 20 mL). The organic phase was then washed with 10% aqueous citric acid, dried over MgSO<sub>4</sub>, and concentrated *in vacuo* to provide a yellow solid. This material was triturated with ether to provide 3.01 g (84.4%) of the title compound. HPLC: R.T.=3.693 min (YMC S5 ODS column 4.6 x 50 mm, 10-90% aqueous methanol over 4 minutes containing 0.2% phosphoric acid, 4 mL/min, monitoring at 220 nm); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.37-7.24 (m, 5H), 6.54 (s, 1H), 4.47 (s, 2H), 3.93 (s, 2H), 3.79 (s, 2H), 1.27 (s, 9H).

#### EXAMPLE 6

D' Preparation of 5-(5-t-Butyl-2-oxazolylalkylthio)-2-[4-(aminomethyl)phenyl]-acetylaminothiazole



The title compound of Example 5 (70% pure, 1.05 g, 1.53 mmol, 1 eq) was dissolved in 40 mL of N,N-dimethylformamide and cooled to -70°C. Excess liquid ammonia (6 mL) was added, and after sealing the reaction vessel, the mixture was allowed to warm to room temperature. After 1 hour, the reaction was diluted with ethyl acetate, washed with water (20 mL) and saturated aqueous NaCl, dried over MgSO<sub>4</sub>, and

concentrated *in vacuo*. The resulting yellow oil was purified by preparative HPLC to provide 270 mg (42.4%) of the title compound. HPLC R.T.= 3.17 min (YMC S5 ODS column 4.6 x 50 mm, 10-90% aqueous methanol over 4 minutes containing 0.2% phosphoric acid, 4 mL/min, monitoring at 220 nm).

5


In the foregoing, there has been provided a detailed description of particular embodiments of the present invention for the purpose of illustration and not limitation. It is to be understood that all other modifications, ramifications and equivalents obvious to those having skill in the art based on this disclosure are intended to be included within the scope of the invention as claimed.

10

## CLAIMS

What is claimed is:

1. A process for the preparation of a compound having the formula I



or a pharmaceutically acceptable salt thereof, wherein:

R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>12</sup> and R<sup>13</sup> are each independently hydrogen, alkyl, aryl

5 or heteroaryl;


R<sup>3</sup>, R<sup>7</sup>, R<sup>10</sup> and R<sup>11</sup> are each independently hydrogen, alkyl, aryl, heteroaryl,

halogen, hydroxy or alkoxy; and

X is CH or N;

which comprises the steps of:

- 10 (a) reacting an arylacetate or an arylacetic acid having the formula II




wherein:

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and X are as described hereinabove;

R is hydrogen, alkyl, aryl or heteroaryl; and

- 15 W is halogen or sulfonate;

with an olefin having the formula III



III

wherein:

Y is CHO, C(O)R, COOR, CONRR<sup>1</sup>, CN, NO<sub>2</sub>, SO<sub>2</sub>OR or SO<sub>2</sub>NRR<sup>1</sup> ;


20 Z is hydrogen, CHO, C(O)R, COOR, CONRR<sup>1</sup>, CN, NO<sub>2</sub>, SO<sub>2</sub>OR or SO<sub>2</sub>NRR<sup>1</sup> ; and

R, R<sup>1</sup> and R<sup>4</sup> are as described hereinabove;

in the presence of a palladium catalyst in a suitable solvent or solvent mixture to form a vinyl-substituted arylacetate or vinyl-substituted arylacetic acid;

(b) reacting the vinyl-substituted arylacetate or vinyl-substituted arylacetic acid  
25 with an oxidizing reagent in a suitable solvent or solvent mixture to form a formylarylacetate or formylarylacetic acid compound;

(c) reacting the formylarylacetate or formylarylacetic acid compound with a 5-(oxazolylalkylthio)-2-aminothiazole compound having the formula VI



VI

30 wherein:

R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> are as described hereinabove;

in the presence of a coupling reagent in a suitable solvent or solvent mixture to form an amide; and

(d) reacting the amide with an amine in the presence of a reducing reagent in a suitable solvent or solvent mixture to form the compound of formula I.

2. The process as recited in Claim 1, wherein the arylacetate or the arylacetic acid in step (a) is a haloarylacetate or a haloarylacetic acid.

3. The process as recited in Claim 2, wherein the haloarylacetic acid is a bromoarylacetic acid.

4. The process as recited in Claim 3, wherein the bromoarylacetic acid is 4-bromophenylacetic acid.

5. The process as recited in Claim 1, wherein the olefin in step (a) is an alkyl acrylate.

6. The process as recited in Claim 1, wherein the palladium catalyst in step (a) is palladium acetate, palladium diacetate or palladium halide.

7. The process as recited in Claim 6, wherein the palladium catalyst is palladium diacetate.

8. The process as recited in Claim 1, wherein the solvent in step (a) is a hydrocarbon, an ether, an amide, a ketone or a mixture thereof.

9. The process as recited in Claim 8, wherein the solvent is the amide and the amide is dimethylformamide.

10. The process as recited in Claim 1, wherein step (a) forms a vinylarylacetate or a vinylarylacetic acid.

11. The process as recited in Claim 1, wherein the oxidizing reagent in step (b) is O<sub>3</sub>, KMnO<sub>4</sub> or NaIO<sub>4</sub>/OsO<sub>4</sub>.

12. The process as recited in Claim 11, wherein the oxidizing reagent is NaIO<sub>4</sub>/OsO<sub>4</sub>.

13. The process as recited in Claim 1, wherein the solvent in step (b) is a hydrocarbon, an ether, an ester, an amide, a mixture thereof or an aqueous mixture thereof.

14. The process as recited in Claim 13, wherein the solvent is the aqueous mixture of an ether and water.

15. The process as recited in Claim 1, wherein the 5-(2-oxazolylalkylthio)-2-aminothiazole compound in step (c) is a 5-(5-substituted-2-oxazolylalkylthio)-2-aminothiazole compound.

16. The process as recited in Claim 15, wherein the 5-(5-substituted-2-oxazolylalkylthio)-2-aminothiazole compound is 5-(5-t-butyl-2-oxazolylalkylthio)-2-aminothiazole.

17. The process as recited in Claim 1, wherein the coupling reagent in step (c) is a carbodiimide, a haloformate or a thionyl halide.

18. The process as recited in Claim 17, wherein the coupling reagent is the thionyl halide.

19. The process as recited in Claim 1, wherein the solvent in step (c) is a hydrocarbon, a halogenated hydrocarbon, an ether, an ester or a mixture thereof.

20. The process as recited in Claim 19, wherein the solvent is the halogenated hydrocarbon and the halogenated hydrocarbon is dichloromethane.

21. The process as recited in Claim 1, wherein the amine in step (d) is a primary amine or a secondary amine.

22. The process as recited in Claim 21, wherein the amine is the primary amine and the primary amine is a primary aliphatic amine.


23. The process as recited in Claim 1, wherein the reducing reagent in step (d) is  $\text{NaBH}_4$ ,  $\text{NaBH}(\text{OAc})_3$  or  $\text{Et}_3\text{SiH/TFA}$ .

24. The process as recited in Claim 23, wherein the reducing reagent is  $\text{NaBH}(\text{OAc})_3$ .

25. The process as recited in Claim 1, wherein the solvent in step (d) is a hydrocarbon, a halogenated hydrocarbon, an ether, an ester or a mixture thereof.

26. The process as recited in Claim 25, wherein the solvent is the ether and the ether is tetrahydrofuran.

27. A process for the preparation of a compound having the formula I



or a pharmaceutically acceptable salt thereof, wherein:

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{12}$  and  $\text{R}^{13}$  are each independently hydrogen, alkyl, aryl

5 or heteroaryl;


$\text{R}^3$ ,  $\text{R}^7$ ,  $\text{R}^{10}$  and  $\text{R}^{11}$  are each independently hydrogen, alkyl, aryl, heteroaryl,

halogen, hydroxy or alkoxy; and

X is CH or N;

which comprises the steps of:

- 10 (a) reacting an alkylarylacetate or alkylarylacetic acid compound having the formula VIII




wherein:

- 15  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and X are as described hereinabove;

R is hydrogen, alkyl, aryl or heteroaryl; and

W is halogen or sulfonate;

with a 5-(2-oxazolylalkylthio)-2-aminothiazole compound having the formula VI



- 20 wherein:

$R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  are as described hereinabove;

in the presence of a coupling reagent and in a suitable solvent or solvent mixture to form an amide; and

- (b) reacting the amide with an amine in a suitable solvent or solvent mixture to  
25 form the compound of formula I.

28. The process as recited in Claim 27, wherein the alkylarylacetate or alkylarylacetic acid in step (a) is a haloalkylarylacetate or a haloalkylarylacetic acid.



29. The process as recited in Claim 28, wherein the haloalkylarylacetic acid is a bromoalkylarylacetic acid.

30. The process as recited in Claim 29, wherein the bromoalkylarylacetic acid is bromomethylphenylacetic acid.

31. The process as recited in Claim 27, wherein the 5-(2-oxazolylalkylthio)-2-aminothiazole compound in step (a) is a 5-(5-substituted-2-oxazolylalkylthio)-2-aminothiazole compound.

32. The process as recited in Claim 31, wherein the 5-(5-substituted-2-oxazolylalkylthio)-2-aminothiazole compound is 5-(5-t-butyl-2-oxazolylalkylthio)-2-aminothiazole.

33. The process as recited in Claim 27, wherein the coupling reagent in step (b) is a carbodiimide, a haloformate or a thionyl halide.

34. The process as recited in Claim 33, wherein the coupling reagent is the carbodiimide and the carbodiimide is an alkylcarbodiimide.

35. The process as recited in Claim 27, wherein the solvent is a hydrocarbon, a halogenated hydrocarbon, an ether, an ester or a mixture thereof.

36. The process as recited in Claim 35, wherein the solvent is the halogenated hydrocarbon and the halogenated hydrocarbon is dichloromethane.


37. The process as recited in Claim 27, wherein the amine in step (b) is a primary amine or a secondary amine.

38. The process as recited in Claim 37, wherein the amine is the primary amine and the primary amine is a primary aliphatic amine.

39. The process as recited in Claim 27, wherein the solvent in step (b) is a hydrocarbon, a halogenated hydrocarbon, an ether, an ester, an amide or a mixture thereof.

40. The process as recited in Claim 39, wherein the solvent is an amide and the amide is dimethylformamide.

41. A process for the preparation of a compound having the formula I



or a pharmaceutically acceptable salt thereof, wherein:

$R^1, R^2, R^4, R^5, R^6, R^8, R^9, R^{12}$  and  $R^{13}$  are each independently hydrogen, alkyl, aryl

5 or heteroaryl;


$R^3, R^7, R^{10}$  and  $R^{11}$  are each independently hydrogen, alkyl, aryl, heteroaryl,

halogen, hydroxy or alkoxy; and

X is CH or N;

which comprises the steps of:

10 (a) reacting an aldehyde having the formula VII



wherein:

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$  and X are as described hereinabove;

with an organometallic reagent in a suitable solvent or solvent mixture to form an alcohol

15 derivative;

(b) reacting the alcohol derivative with a halide; and

(c) reacting the halide compound with an excess of a primary amine or a secondary amine in a suitable solvent or solvent mixture to form the compound of formula I.

42. The process as recited in Claim 41, wherein the organometallic reagent in step (a) is methylmagnesium bromide.


43. The process as recited in Claim 41, wherein the solvent in step (a) is ether.

44. The process as recited in Claim 41, wherein the halide in step (b) is thionyl chloride.

45. The process as recited in Claim 41, wherein the solvent in step (c) is ethanol.

46. A process for the preparation of a formylarylacetate or formylarylacetic acid which comprises the following steps:

(a) reacting a haloarylacetate or haloarylacetic acid having formula II



5 wherein:

R is hydrogen, alkyl, aryl or heteroaryl;


R<sup>1</sup> and R<sup>2</sup> are each independently hydrogen, alkyl, aryl or heteroaryl;

R<sup>3</sup> is hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy;

W is halogen or sulfonate; and

10 X is CH or N;

with an olefin having the formula III



III

wherein:

R<sup>4</sup> is hydrogen, alkyl, aryl or heteroaryl;

15 Y is CHO, C(O)R, COOR, CONRR<sup>1</sup>, CN, NO<sub>2</sub>, SO<sub>2</sub>OR or SO<sub>2</sub>NRR<sup>1</sup> ;

Z is hydrogen, CHO, C(O)R, COOR, CONRR<sup>1</sup>, CN, NO<sub>2</sub>, SO<sub>2</sub>OR or SO<sub>2</sub>NRR<sup>1</sup> ; and

R and R<sup>1</sup> are as described hereinabove;

in the presence of a palladium catalyst in a suitable solvent or solvent mixture to form a vinyl-substituted arylacetate or vinyl-substituted arylacetic acid; and

20 (b) reacting the vinyl-substituted arylacetate or vinyl-substituted arylacetic acid with an oxidizing reagent in a suitable solvent or solvent mixture to form the formylarylacetate or formylarylacetic acid compound.

47. The process as recited in Claim 46, wherein the olefin in step (a) is alkyl acrylate.

48. The process as recited in Claim 47, wherein the alkyl acrylate is ethyl acrylate.

49. The process as recited in Claim 46, wherein the oxidizing reagent in step (b) is  $O_3$ ,  $KMnO_4$  or  $NaIO_4/OsO_4$ .

50. The process as recited in Claim 49, wherein the oxidizing reagent is  $NaIO_4/OsO_4$ .

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/14154

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D417/12 C07D417/14 C07C69/618 C07C67/343 C07C59/74  
C07C51/373 C07C69/73 C07C67/31 C07C67/333

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SMITH K ET AL: "Synthesis of a novel macrocyclic lactone system" HETEROCYCLES, vol. 37, no. 3, May 1994 (1994-05), pages 1865-1872, XP002181595 the whole document, particularly page 1868, scheme 2 ---	46-50
P, X	US 6 214 852 B1 (KIM K S ET AL) 10 April 2001 (2001-04-10) the whole document	1-50
E	& WO 01 44241 A (BRISTOL-MYERS SQUIBB CO.) 21 June 2001 (2001-06-21) the whole document --- -/--	1-50

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

31 October 2001

Date of mailing of the international search report

13/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Allard, M

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/14154

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 99 24416 A (BRISTOL-MYERS SQUIBB COMPANY) 20 May 1999 (1999-05-20)  cited in the application  the whole document  -----</p>	1,27,41

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/14154

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6214852	B1	10-04-2001	US 6262096 B1 17-07-2001
			US 6040321 A 21-03-2000
			AU 1950601 A 25-06-2001
			WO 0144241 A1 21-06-2001
			US 2001004639 A1 21-06-2001
			AU 2062701 A 25-06-2001
			AU 2726401 A 25-06-2001
			WO 0144217 A1 21-06-2001
			WO 0144242 A1 21-06-2001
			US 2001006976 A1 05-07-2001
WO 9924416	A	20-05-1999	AU 730607 B2 08-03-2001
			AU 1295599 A 31-05-1999
			BR 9814124 A 03-10-2000
			CN 1278806 T 03-01-2001
			EP 1042307 A1 11-10-2000
			NO 20002153 A 11-05-2000
			PL 340540 A1 12-02-2001
			TR 200001344 T2 21-09-2000
			WO 9924416 A1 20-05-1999
			US 6040321 A 21-03-2000
			US 6262096 B1 17-07-2001